Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904540 · ClinicalTrials.gov registry record · Phase 4
Topical Lidocaine Patch in Low Back Pain
A Phase 4 study of Acute and Chronic Non-radicular LBP, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 131
- Enrollment target
- 7
- Study locations
NCT00904540 is a Phase 4 study of Acute and Chronic Non-radicular LBP that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 131 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT00904540, a Phase 4 study of Acute and Chronic Non-radicular LBP, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 131 participants
- Enrollment target
- 7
- Study locations
Study Summary
Patients with acute or chronic Lower Back Pain (LBP) participated in a Phase IV clinical trial to assess the effectiveness of Lidoderm administered once daily (q24h) for 2 weeks in the treatment of acute and chronic LBP.
Conditions Studied
Interventions
- DRUG Lidoderm®
Study Locations (7)
Arizona
- - Phoenix
California
- - Mill Valley
Florida
- - Weston
New York
- - Bethpage
North Carolina
- - Charlotte
Pennsylvania
- - Allentown
Wisconsin
- - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2002-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904540
The ClinicalTrials.gov registry entry for NCT00904540 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute and Chronic Non-radicular LBP appearing as the primary indexed condition, and to 1 intervention - of which Lidoderm® is the first listed.
NCT00904540 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00904540 about?
NCT00904540 is a clinical study titled "Topical Lidocaine Patch in Low Back Pain". Patients with acute or chronic Lower Back Pain (LBP) participated in a Phase IV clinical trial to assess the effectiveness of Lidoderm administered once daily (q24h) for 2 weeks in the treatment of acute and chronic LBP.
What is the current status of trial NCT00904540?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 131 participants. The study started on 2002-03.
What conditions does trial NCT00904540 study?
This clinical trial studies the following conditions: Acute and Chronic Non-radicular LBP.
What interventions are being tested in trial NCT00904540?
The interventions under investigation include: Lidoderm® (DRUG).
Who is sponsoring clinical trial NCT00904540?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00904540 being conducted?
This trial has 7 study locations across Arizona, California, Florida, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.